Raymond Mallory, Walker Elizabeth, Dave Ishaan, Dedhia Kavita
Emory University School of Medicine, Department of Otolaryngology - Head and Neck Surgery, Division of Pediatric Otolaryngology, USA.
Emory University School of Medicine, Department of Pediatrics, USA.
Int J Pediatr Otorhinolaryngol. 2019 Sep;124:68-75. doi: 10.1016/j.ijporl.2019.05.038. Epub 2019 May 29.
Approximately 60% of congenital pediatric hearing loss is of genetic etiology. To evaluate non-syndromic sensorineural hearing loss (NSSNHL), guidelines emphasize the use of comprehensive genetic testing (CGT) with next generation sequencing (NGS), yet these tests have limited accessibility, and potential CGT results may not be well understood. Thus, our objective was to analyze genetic testing practices and results for pediatric patients with NSSNHL.
This was a retrospective chart review of pediatric patients (<18 years) diagnosed with NSSNHL from 2014 to 2017 at a tertiary pediatric hospital. Demographics, clinical data, CGT results, genetic testing practices and referral patterns were recorded and descriptively analyzed. Logistic regression models identified patient characteristics associated with pathogenic variants (PV) and variants of unknown significance (VOUS).
430 patients with congenital NSSNHL were included in the study. Genetic testing was ordered for 28% (n = 122) and resulted for 16% (n = 68). Most of the ordered tests (89%, n = 109) were the CGT panel. A majority (62%, n = 97) of the time in which genetic testing was not ordered, a referral for genetics consultation was placed. Amongst those with CGT results, a definitive genetic etiology was identified in 25% (n = 13), with less than half due to variants of GJB2/6. At least one PV was identified for 33% (n = 18), while at least one VOUS for 93% (n = 51). There were no significant differences in PV presence or number of VOUS across any characteristic except race. When compared to Caucasians, African Americans had significantly higher rates of VOUS with a rate ratio and 95% CI of 1.61 [1.11-2.34], p = 0.01, and Asians trended towards higher rates (1.96 [0.95-4.05], p = 0.06).
CGT is of high utility in the identification of relevant genetic variants and definitive genetic etiologies for pediatric patients with NSSNHL. Though guidelines recommend the early use of CGT, there are many barriers to appropriate testing and counseling, leading to low rates of CGT use at this single institution.
约60%的先天性小儿听力损失是由遗传病因引起的。为评估非综合征性感音神经性听力损失(NSSNHL),相关指南强调采用下一代测序(NGS)进行全面基因检测(CGT),然而这些检测的可及性有限,且潜在的CGT结果可能未得到充分理解。因此,我们的目标是分析NSSNHL小儿患者的基因检测实践及结果。
这是一项对2014年至2017年在一家三级儿科医院被诊断为NSSNHL的小儿患者(<18岁)进行的回顾性病历审查。记录并描述性分析人口统计学、临床数据、CGT结果、基因检测实践及转诊模式。逻辑回归模型确定与致病变异(PV)和意义未明变异(VOUS)相关的患者特征。
430例先天性NSSNHL患者纳入本研究。28%(n = 122)的患者接受了基因检测医嘱,其中结果可用的占16%(n = 68)。大多数接受医嘱的检测(89%,n = 109)为CGT检测板。在未接受基因检测医嘱的情况中,大部分时间(62%,n = 97)会转诊至遗传学咨询。在有CGT结果的患者中,25%(n = 13)确定了明确的遗传病因,其中因GJB2/6变异导致的不到一半。33%(n = 18)的患者至少鉴定出一个PV,而93%(n = 51)的患者至少鉴定出一个VOUS。除种族外,在任何特征方面,PV的存在或VOUS的数量均无显著差异。与白种人相比,非裔美国人的VOUS发生率显著更高,率比及95%置信区间为1.61 [1.11 - 2.34],p = 0.